Table 2.
Stratification of cohort by sex
| All women (n=253 690) | All men (n=206 147) | Women with gout (n=2526) | Men with gout (n=13 345) | ||
|---|---|---|---|---|---|
| Diagnosed with COVID-19 | 8858 (3·5%) | 8040 (3·9%) | 166 (6·6%) | 674 (5·1%) | |
| COVID-19-related death | 399 (0·2%) | 712 (0·3%) | 34 (1·3%) | 102 (0·8%) | |
| Age, years | |||||
| <60 | 47 559 (18·7%) | 39 486 (19·2%) | 131 (5·2%) | 1306 (9·8%) | |
| 60–69 years | 83 269 (32·8%) | 63 655 (30·9%) | 529 (20·9%) | 3534 (26·5%) | |
| 70–74 years | 59 851 (23·6%) | 47 446 (23·0%) | 665 (26·3%) | 3522 (26·4%) | |
| >74 years | 63 011 (24·8%) | 55 560 (27·0%) | 1201 (47·5%) | 4983 (37·3%) | |
| Body-mass index, mg/m2 | 27·03 (5·14) | 27·79 (4·17) | 31·97 (6·37) | 30·06 (4·54) | |
| Townsend deprivation index | −1·37 (3·02) | −1·33 (3·11) | −0·72 (3·27) | −1·19 (3·14) | |
| Ethnicity | |||||
| White British | 239 456 (94·4%) | 194 180 (94·2%) | 2286 (90·5%) | 12 647 (94·8%) | |
| Black British | 5653 (2·2%) | 5546 (2·7%) | 99 (3·9%) | 361 (2·7%) | |
| Asian British | 4889 (1·9%) | 3429 (1·7%) | 73 (2·9%) | 183 (1·4%) | |
| Other ethnicity | 3692 (1·5%) | 2992 (1·5%) | 68 (2·7%) | 154 (1·2%) | |
| Smoking status | |||||
| Never smoker | 152 649 (60·2%) | 103 808 (50·4%) | 1313 (52·0%) | 5582 (41·8%) | |
| Current smoker | 79 367 (31·3%) | 78 121 (37·9%) | 1007 (39·9%) | 6554 (49·1%) | |
| Ex-smoker | 21 674 (8·5%) | 24 218 (11·7%) | 206 (8·2%) | 1209 (9·1%) | |
| Medical history | |||||
| Asthma | 24 955 (9·8%) | 15 902 (7·7%) | 522 (20·7%) | 1409 (10·6%) | |
| Cancer | 36 642 (14·4%) | 33 269 (16·1%) | 588 (23·3%) | 2790 (20·9%) | |
| Cerebrovascular diseases | 6734 (2·7%) | 8731 (4·2%) | 222 (8·8%) | 998 (7·5%) | |
| Chronic kidney disease | 7525 (3·0%) | 7340 (3·6%) | 634 (25·1%) | 1815 (13·6%) | |
| Chronic obstructive pulmonary disease | 7353 (2·9%) | 7778 (3·8%) | 267 (10·6%) | 896 (6·7%) | |
| Dementia | 1427 (0·6%) | 1465 (0·7%) | 49 (1·9%) | 153 (1·1%) | |
| Diabetes | 14 056 (5·5%) | 19 414 (9·4%) | 673 (26·6%) | 2389 (17·9%) | |
| Heart failure | 4018 (1·6%) | 6962 (3·4%) | 316 (12·5%) | 1353 (10·1%) | |
| Hypertensive diseases | 61 929 (24·4%) | 65 719 (31·9%) | 1788 (70·8%) | 7754 (58·1%) | |
| Immunodeficiencies | 983 (0·4%) | 857 (0·4%) | 38 (1·5%) | 99 (0·7%) | |
| Interstitial lung disease | 930 (0·4%) | 1083 (0·5%) | 47 (1·9%) | 145 (1·1%) | |
| Ischaemic heart disease | 16 660 (6·6%) | 29 970 (14·5%) | 614 (24·3%) | 3500 (26·2%) | |
| Lipoprotein disorders | 27 541 (10·9%) | 36 372 (17·6%) | 837 (33·1%) | 4210 (31·5%) | |
| Liver failure | 188 (0·1%) | 314 (0·2%) | 10 (0·4%) | 48 (0·4%) | |
| Osteoarthritis | 48 027 (18·9%) | 33 021 (16·0%) | 1167 (46·2%) | 3745 (28·1%) | |
| Pulmonary heart disease | 3431 (1·4%) | 3675 (1·8%) | 148 (5·9%) | 475 (3·6%) | |
| Medical treatment | |||||
| Colchicine* | 834/190 664 (0·4%) | 3108/150 734 (2·1%) | 334/2250 (14·8%) | 1734/11 789 (14·7%) | |
| Urate-lowering therapy* | 1479/190 664 (0·8%) | 9111/150 734 (6·0%) | 1479/2250 (65·7%) | 9111/11 789 (77·3%) | |
Data are n (%), mean (SD), or n/N (%).
*
n=341 398 subset.